APOE and Alzheimer disease: We then generated an antibody to the APOE Christchurch binding domain and demonstrated its ability to inhibit ApoE binding to heparan sulfate, supporting the possibility of developing competitors of ApoE binding to HSPG that could be used in the treatment and prevention of AD.